LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Fresh Red Blood Cells Transfusions No Better Than Older Ones

By LabMedica International staff writers
Posted on 23 Dec 2019
Print article
Image: Among critically ill pediatric patients, the use of fresh red blood cells did not reduce the incidence of new or progressive multiple organ dysfunction syndrome (including mortality),  compared with standard-issue red blood cells (Photo courtesy of The Children`s Hospital Westmead)
Image: Among critically ill pediatric patients, the use of fresh red blood cells did not reduce the incidence of new or progressive multiple organ dysfunction syndrome (including mortality), compared with standard-issue red blood cells (Photo courtesy of The Children`s Hospital Westmead)
Red blood-cell transfusions are commonly administered in critically ill children who have illnesses that increase the need for transfusion, such as trauma, cancer chemotherapy, major surgery with significant intraoperative bleeding, and conditions such as sickle cell disease and thalassemia.

Transfusion with red blood cells is the only way to rapidly treat severe anemia that could be life-threatening. Red blood cells are stored in blood banks as red-cell units for up to 42 days. Some studies published over the past few decades have suggested that transfusion with red blood-cell units stored for longer periods might be less beneficial than transfusion with fresher red-cell units.

A large international team of scientists led by critical care staff at Sainte-Justine University Hospital Centre (Montreal, QC, Canada) undertook a randomized trial that recruited patients admitted to pediatric intensive care units in 50 medical centers. The study began in February 2014 and ended in November 2018. In the study there were 1,461 children ranging in age from 3 days to 16 years who were admitted to pediatric intensive care units and were recruited in the USA (29 sites), Canada (10 sites), France (eight sites), Italy (two sites), and Israel (one site); Sainte-Justine University Hospital was the coordinating center in Canada and recruited the greatest number of patients (over 160).

During the course of the study, half of the patients received transfusions with fresh red blood cells stored for seven days or less and half received transfusions with older red cells. The primary outcome measured was the development of new or progressive multiple-organ dysfunction (impairment of one or more organs). The team found that fresh red cells did not reduce the incidence of new or progressive multiple-organ dysfunction or death compared to older red cells and that the outcomes were not significantly different between the two groups. About 20.2% of those who received fresh red cells experienced new or progressive organ dysfunction, while 18.2% of those who received older red cells experienced similar dysfunction.

The study did not examine whether the use of the oldest red cells allowable (more than 35 days) affects outcomes, or whether fresh red cells affect outcomes for children requiring large-volume red cell transfusions. The children in this study received low-volume red cell transfusions. The authors concluded that among critically ill pediatric patients, the use of fresh red blood cells did not reduce the incidence of new or progressive multiple organ dysfunction syndrome (including mortality) compared with standard-issue red blood cells. The study was published on December 10, 2019 in the Journal of the American Medical Association.

Related Links:
Sainte-Justine University Hospital Centre

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.